TheUS Food and Drug Administration (FDA) has accepted Bayer's supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), for the treatment of patients with metastatic ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. The Food and Drug Administration (FDA) ...

Aiming to make noise in oncology, Bayer is counting on prostate cancer drug Nubeqa as a potential blockbuster. On Tuesday, the company took a step toward that goal, earning priority review status for ...

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. A supplemental new drug application has ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral ...

FRANKFURT (Reuters) -A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The sNDA is seeking label expansion of Nubeqa in combination with androgen ...

FRANKFURT, July 17 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, ...

Bayer is spelling out an even more bullish estimate for Nubeqa’s blockbuster potential, thanks to a trial win in a new prostate cancer frontier for the drug. But the German drugmaker still faces an ...

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with ...